G1 Therapeutics Inc (STU:G1H)
€ 6.39 0 (0%) Market Cap: 339.15 Mil Enterprise Value: 327.68 Mil PE Ratio: 0 PB Ratio: 15.31 GF Score: 32/100

Q3 2021 G1 Therapeutics Inc Earnings Call Transcript

Nov 03, 2021 / 12:30PM GMT
Release Date Price: €13.66 (+5.85%)
Operator

Good day, and thank you for standing by. Welcome to the G1 Therapeutics Third Quarter 2021 Financial Results Conference Call. (Operator Instructions)

I would now like to turn the conference over to your speaker today, Will Roberts. Thank you. Please go ahead.

William C. Roberts
G1 Therapeutics, Inc. - VP of IR & Corporate Communications

Thank you, Gail. Good morning, everyone, and welcome to the G1 conference call to discuss our third quarter 2021 financial results and business update. The press release on these financial results was issued this morning and can be found in the News section of our corporate website, g1therapeutics.com.

On this morning's call, the team will provide a business overview of the third quarter of 2021, including an update on our commercial progress in that period with COSELA, which was approved by the U.S. Food and Drug Administration on February 12, 2021, to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot